Table 1 Clinical effect of HDF, symptoms
Study [Ref] | Study design | Modality/number | Results |
|---|---|---|---|
Dialysis related amyloidosis (DRA) | |||
Locattelli [16], Lombardy/Italy | Prospective obsevation | HDF (HF) versus LFHD:1082/6298, | DRA:42.2%r reduction, Mortality:ns |
Nakai [17], Japan | Retrospective obsevation | HDF 77 versus LFHD (total 1192) | DRA 97% reduction P < 0.0001 |
Dialysis related hypotension (DRH) | |||
Locattelli [19], Italian study | RCT | Pre-ol-HF/HDF versus LFHD: 150/75/75 | DRH 54% reduction |
ESHOL study [20], Catalonian/Spain | RCT sub-analysis | Post-ol-HDF versus HFHD: 450/456 | DRH 28% reduction |
Donauer [22], Germany | Crossover,, single center | Post-ol-HDF versus Cool HD: 25 session | DRH: prevention as same as post-ol-HDF & Cool HD |
Smith [23], Glasgow/UK | Crossover, blind, single center | Post-ol-HDF versus HFHD: 50 | Recovery time: longer DRH:52% higher |
Anemia | |||
Locattelli [36], Italian study | RCT sub-analysis | Pre-ol-HF/HDF versus LFHD: 150/75/75 | ns |
Pedrini [37], Italy, Czech, Slovenia, | Retrospective cohort | mixed dilusion HDF versus post-ol-HDF; 87/87 | Mixed HDF:Hgb up (p = 0.0124) |
Quality of life (QOL) | |||
Karkar [38], Saudi Arabia | RCT | Post-ol-HDF versus HFHD:32/32 | Better |
Restless legs syndrome (RLS) | |||
Sakurai 2013 [45], Japan | Retrospective, observation | Pre-ol-HDF 17 | RLS prevention: αMG removal rate > 35% |
Inflammation | |||
Ariza [34], Spain | Crossover study | HFHD versus post-ol-HDF versus mid-dilution HDF:12 | HDF: decrease CD14, CD16, monocyte |
Dutch CONTRAST [35], The Netherlands | RCT sub-analysis | Post-ol-HDF versus LFHD: 356/358 | Decease CRP |